SynthesisJournal of the American Academy of Dermatology2022
Treatment of immune checkpoint inhibitor-mediated psoriasis: A systematic review.
Synthesis in Journal of the American Academy of Dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Skin Reactions and Other Underappreciated Dermatologic Side Effects of Cancer Therapies.Current treatment options in oncology · 2025Review
- Clinical features, treatment, and outcomes of nivolumab induced psoriasis.Investigational new drugs · 2025Article
- Association of vitiligo with immune-checkpoint inhibitor therapy: A systematic review.JAAD international · 2025Article
- Toripalimab induces exacerbation of psoriasis in an esophageal cancer patient: a case report.Frontiers in oncology · 2025Article
- Psoriasis caused by camrelizumab in a patient with esophageal cancer: a case report.Frontiers in medicine · 2025Article
- Psoriasis in the Era of Targeted Cancer Therapeutics: A Systematic Review on De Novo and Pre-existing Psoriasis in Oncologic Patients Treated with Emerging Anti-neoplastic Agents.Dermatology and therapy · 2024Review
- Research Progress on Chitosan Microneedle Arrays in Transdermal Drug Delivery.International journal of nanomedicine · 2024Review
- Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Transdermal Delivery of Indirubin-Loaded Microemulsion Gel: Preparation, Characterization and Anti-Psoriatic Activity.International journal of molecular sciences · 2022Article
- Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors.Immunotherapy advances · 2022Article
- Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors.Anais brasileiros de dermatologiaReview
- Updates in toxicities associated with immune checkpoint inhibitors.Expert review of clinical immunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.